Form 4: Turn Therapeutics Director Boosts Stake

Arthur F. Golden, a Director at Turn Therapeutics Inc., purchased 20,532 shares of common stock at a weighted average price of $2.87 per share.

Summary

• Arthur F. Golden, a Director of Turn Therapeutics Inc. (TTRX), acquired 20,532 shares of the company's common stock.
• The transaction is reported to have occurred on November 21, 2025.
• The shares were purchased at a weighted average price of $2.87 per share, with individual transaction prices ranging from $2.66 to $3.25.
• Following this transaction, Mr. Golden beneficially owns 50,734 shares of Turn Therapeutics Inc. common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase.
• The reported beneficial ownership includes certain restricted stock units (RSUs) granted under the Issuer's 2025 Omnibus Incentive Plan, which are subject to applicable vesting schedules and continuous service.

Sentiment

Score: 7

Explanation: The purchase of shares by a director indicates confidence in the company's future, which is generally a positive signal for investors.

Positives

• A company director, Arthur F. Golden, increased his direct ownership in Turn Therapeutics Inc. by purchasing 20,532 shares, signaling confidence in the company's future.
• Insider buying can often be interpreted by the market as a positive indicator of management's belief in the company's valuation and prospects.
• The transaction was executed under a Rule 10b5-1 plan, which demonstrates a pre-planned investment strategy and adherence to insider trading regulations.

Risks

• The filing itself does not detail specific company risks, but general investment risks apply to any stock purchase, including market volatility and potential declines in share value.
• The value of the acquired shares is subject to market fluctuations and the overall performance of Turn Therapeutics Inc.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the 'Issuer'), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Industry Context

Insider purchases, such as this one by a director, are often viewed by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that future prospects are strong. This can potentially boost investor confidence in Turn Therapeutics Inc. relative to its peers.

Corporate Governance

Related Party Transactions

• Arthur F. Golden, a Director of Turn Therapeutics Inc., purchased 20,532 shares of the company's common stock. This is a direct transaction between a company insider and the company's equity.

Stakeholder Impact

• Shareholders: May view the director's purchase as a sign of confidence, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees: No direct impact mentioned, but positive investor sentiment could indirectly benefit employee morale or stock-based compensation value.
• Management: The purchase by a director reinforces alignment of interests between management and shareholders.

Next Steps

• The company will continue to operate its business.
• The reporting person will continue to hold the beneficially owned shares, subject to market conditions and personal investment decisions.

Key Dates

Recommendation

The director's purchase of additional shares is a positive signal, indicating confidence in Turn Therapeutics Inc.'s future prospects. However, a single insider transaction, while noteworthy, typically warrants a 'hold' recommendation rather than a 'buy' without further fundamental analysis or additional corroborating positive news. It suggests the stock may be undervalued or has strong potential, but investors should consider this alongside other financial and strategic information.

Keywords

Turn Therapeutics, TTRX, Insider Purchase, Director Stock Buy, Form 4, Equity Acquisition, Arthur F. Golden, Common Stock, Rule 10b5-1